SavedAdd your journal

Journals / Journal of Health Sciences and Medicine / 2026 / Volume: 9 Issue: 4

Vaccination rate and vaccine hesitancy of pregnant women, comparison of causes with epidemiological factors during SARS-CoV-2 pandemic

Bilge Doğan Taymur(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL SANCAKTEPE ŞEHİR PROF. DR. İLHAN VARANK SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ)0000-0002-1246-7594
Güldeniz Toklucu(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL SANCAKTEPE ŞEHİR PROF. DR. İLHAN VARANK SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ)0000-0001-9041-3471
Pages
—
Publication Date
2026-07-20
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall acceptance rate of the SARS-CoV-2 vaccine was 47.4%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Vaccine hesitancy remains a major challenge in public health, particularly among pregnant women, who represent a high-risk group for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
📊
Key Findings & Data:This study aimed to evaluate SARS-CoV-2 vaccine acceptance and to identify factors related to vaccine hesitancy among pregnant women.
💡
Conclusion & Impact:The overall acceptance rate of the SARS-CoV-2 vaccine was 47.4%.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Vaccine hesitancy · SARS-CoV-2 · pregnancy

Abstract

Aims: Vaccine hesitancy remains a major challenge in public health, particularly among pregnant women, who represent a high-risk group for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to evaluate SARS-CoV-2 vaccine acceptance and to identify factors related to vaccine hesitancy among pregnant women. This hospital-based, cross-sectional study was conducted among pregnant women attending routine antenatal care clinics at a tertiary healthcare center. Methods: Pregnant women who voluntarily consented to participate were included in the study. Data were collected using a structured questionnaire covering sociodemographic characteristics, obstetric history, presence of chronic disease, history of SARS-CoV-2 infection, vaccination status, and reasons for vaccine hesitancy. During pregnancy, vaccinated and unvaccinated groups were compared using appropriate statistical techniques. Results: A total of 249 pregnant women were included. The overall acceptance rate of the SARS-CoV-2 vaccine was 47.4%. No statistically significant differences were observed between vaccinated and unvaccinated women in terms of age, education level, employment status, income level, obstetric characteristics, presence of chronic disease, or history of SARS-CoV-2 infection (p>0.05). Gestational age was significantly higher among unvaccinated women compared with vaccinated women (p<0.01). The most commonly reported reason for vaccine hesitancy was concern about potential harm to the fetus, followed by lack of recommendation from healthcare professionals and fear of side effects. Conclusion: Vaccine hesitancy among pregnant women remains an important public health issue. Concerns related to fetal safety appear to be the primary barrier to SARS-CoV-2 vaccine acceptance. These findings provide practical evidence to guide antenatal counseling and public health communication strategies aimed at increasing vaccine uptake among pregnant women. Addressing pregnancy-specific safety concerns through targeted education may improve immunization coverage in this high-risk population.

🔖

Cite This Article

Taymur, B. D., Toklucu, G. (2026). Vaccination rate and vaccine hesitancy of pregnant women, comparison of causes with epidemiological factors during SARS-CoV-2 pandemic. Journal of Health Sciences and Medicine, Volume: 9 Issue: 4. https://doi.org/10.32322/jhsm.1883733

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (29)

  1. World Health Organization. COVID-19 Weekly Epidemiological Update: Data as Received by WHO From National Authorities, as of 22 November 2020, 10 am CET. World Health Organization; 2020.
  2. Oxford Analytica. Vaccine hesitancy could derail COVID-19 control. Expert Briefings. 2020. doi:10.1108/OXAN-DB252756
  3. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020;396(10263):1614-1616. doi:10.1016/S0140-6736(20)32318-7
  4. Iwasaki A, Omer SB. Why and how vaccines work. Cell. 2020;183(2):290-295. doi:10.1016/j.cell.2020.09.040
  5. McAteer J, Yildirim I, Chahroudi A. The VACCINES Act: deciphering vaccine hesitancy in the time of COVID-19. Clin Infect Dis. 2020;71(15): 703-705. doi:10.1093/cid/ciaa433
  6. Wang J, Jing R, Lai X, et al. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines (Basel). 2020;8(3):482. doi: 10.3390/vaccines8030482
  7. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine: a survey of U.S. adults. Ann Intern Med. 2020;173(12):964-973. doi:10.7326/M20-3569
  8. Pogue K, Jensen JL, Stancil CK, et al. Influences on attitudes regarding potential COVID-19 vaccination in the United States. Vaccines (Basel). 2020;8(4):582. doi:10.3390/vaccines8040582
  9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
  10. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
  11. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23): 2187-2201. doi:10.1056/NEJMoa2101544
  12. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine. Lancet. 2021;397(10269):99-111. doi:10.1016/S0140-6736(20)32661-1
  13. Centers for Disease Control and Prevention. Data on COVID-19 During Pregnancy: Severity of Maternal Illness. Centers for Disease Control and Prevention; 2021. Accessed August 6, 2021.
  14. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of COVID-19 in pregnancy. BMJ. 2020;370:m3320. doi:10.1136/bmj.m3320
  15. Abdelazim IA, AbuFaza M, Al-Munaifi S. COVID-19 positive woman presented with preterm labor: case report. Gynecol Obstet Reprod Med. 2021;27(3):294-296. doi:10.21613/GORM.2021.1170
  16. Dey M, Singh S, Tiwari R, Nair VG, Arora D, Tiwari S. Pregnancy outcome in first 50 SARS-CoV-2 positive patients at our center. Gynecol Obstet Reprod Med. 2021;27(1):11-16. doi:10.21613/GORM.2021.1176
  17. Centers for Disease Control and Prevention. People With Certain Medical Conditions. Centers for Disease Control and Prevention; 2020. Accessed September 7, 2020.
  18. Smith DD, Pippen JL, Adesomo AA, Rood KM, Landon MB, Costantine MM. Exclusion of pregnant women from clinical trials during the COVID-19 pandemic. Am J Perinatol. 2020;37(8):792-799. doi:10.1055/ s-0040-1712103
  19. American College of Obstetricians and Gynecologists. Vaccinating Pregnant and Lactating Patients Against COVID-19. American College of Obstetricians and Gynecologists; 2020. Accessed April 25, 2020.
  20. Society for Maternal-Fetal Medicine. SARS-CoV-2 Vaccination in Pregnancy. Society for Maternal-Fetal Medicine; 2020. Accessed April 25, 2020.
  21. Özceylan G, Toprak D, Esen ES. Vaccine rejection and hesitation in Turkey. Hum Vaccin Immunother. 2020;16(5):1034-1039. doi:10.1080/21645515.2020.1717182
  22. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine hesitancy: causes, consequences, and a call to action. Am J Prev Med. 2015;49(6 Suppl 4): S391-S398. doi:10.1016/j.amepre.2015.06.009
  23. Offeddu V, Tam CC, Yong TT, et al. Coverage and determinants of influenza vaccine among pregnant women. BMC Public Health. 2019;19: 890. doi:10.1186/s12889-019-7172-8
  24. Wang J, Sun D, Abudusaimaiti X, Vermund SH, Li D, Hu Y. Low awareness of influenza vaccination among pregnant women. Hum Vaccin Immunother. 2019;15(11):2637-2643. doi:10.1080/21645515.2019. 1596713
  25. World Health Organization. WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines. World Health Organization; 2020. Accessed December 3, 2020.
  26. Hu Y, Wang Y, Liang H, Chen Y. Seasonal influenza vaccine acceptance among pregnant women. Int J Environ Res Public Health. 2017;14(12): 1551. doi:10.3390/ijerph14121551
  27. Turan G, Kul G. Tetanus immunization in pregnant women: the factors affecting maternal evaluation, tetanus vaccination and vaccination rate. Perinat J. 2019;27(3):137-142. doi:10.2399/prn.19.0273003
  28. Iacobucci G. COVID-19 and pregnancy: vaccine hesitancy and how to overcome it. BMJ. 2021;375:n2862. doi:10.1136/bmj.n2862
  29. Simsekoglu N, Akyuz E, Guven R, Pasin O. Attitudes toward COVID-19 vaccines during pregnancy and breastfeeding. Front Public Health. 2024;12:1286891. doi:10.3389/fpubh.2024.1286891